VAXCYTE INC shares rose 57% in morning trading after its experimental pneumococcal vaccine matched rival products in a late-stage trial. The study evaluated the VAX-31 vaccine against established therapies in older adults. The successful trial positions the company to challenge established market leaders in the adult vaccine sector.
Vaxcyte Shares Jump 57 Percent on Trial Success
Vaxcyte shares surged after its experimental pneumococcal vaccine met primary goals in a late stage study. The vaccine showed strong immune responses compared to rival treatments. The company plans to apply for US approval in 2028.
Xurve View
Insights:
Xurve View











